Patent application number | Description | Published |
20080262012 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention. | 10-23-2008 |
20080262024 | RIFAXIMIN COMPOSITIONS AND METHOD OF USE - Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use. | 10-23-2008 |
20080262220 | POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 10-23-2008 |
20080262232 | PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 10-23-2008 |
20090011020 | Gastroresistant Pharmaceutical Formulations Containing Rifaximin - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 01-08-2009 |
20090081133 | Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations - Mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients. | 03-26-2009 |
20100010028 | USE OF POLYOLS TO OBTAIN STABLE POLYMORPHOUS FORMS OF RIFAXIMIN - Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described. | 01-14-2010 |
20100330129 | Gastroresistant Pharmaceutical Formulations Containing Rifaximin - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 12-30-2010 |
20110086871 | RIFAXIMIN COMPOSITIONS AND METHOD OF USE - Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use. | 04-14-2011 |
20110152516 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention. | 06-23-2011 |
20110160448 | POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 06-30-2011 |
20110160449 | PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 06-30-2011 |
20120035202 | RIFAXIMIN COMPOSITIONS AND METHOD OF USE - Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use. | 02-09-2012 |
20120088726 | MUCOADHESIVE XYLOGLUCAN-CONTAINING FORMULATIONS USEFUL IN MEDICAL DEVICES AND IN PHARMACEUTICAL FROMULATIONS - Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients. | 04-12-2012 |
20120202989 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention. | 08-09-2012 |
20120203000 | POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 08-09-2012 |
20120214989 | PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 08-23-2012 |
20120238630 | COMPOSITIONS COMPRISING NONSTEROIDAL ANTI - INFLAMMATORY DRUGS - The present invention describes liquid compositions comprising pharmaceutically active principles, like scarcely water-soluble, nonsteroidal anti-inflammatory drugs, in particular, but not exclusively, flurbiprofen (FP), processes for their manufacture and their therapeutic use. The liquid compositions comprising FP in association with natural polymers, like xyloglucans (XG), and pharmaceutically acceptable excipients like glycerol, are suitable to be used for pharmaceutical uses and are characterized by good tolerability, therapeutic efficacy, stability and palatability. | 09-20-2012 |
20120245192 | PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN, PROCESSES FOR THEIR OBTAINMENT AND METHOD OF TREATING INTESTINAL DISEASE - Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form β, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days. | 09-27-2012 |
20120258166 | RIFAXIMIN COMPOSITIONS AND METHOD OF USE - Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use. | 10-11-2012 |
20130004576 | RIFAXIMIN POWDER, PROCESS FOR PREPARING THE SAME AND CONTROLLED RELEASE COMPOSITIONS CONTAINING SAID RIFAXIMIN USEFUL FOR OBTAINING A LONG-LASTING EFFECT - The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient. | 01-03-2013 |
20130028971 | Pharmaceutical Compositions Comprising Rifaximin, Processes For Their Preparation And Their Use In The Treatment Of Vaginal Infections - The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided. | 01-31-2013 |
20130045946 | SULODEXIDE FOR USE IN THE TREATMENT OF PATHOLOGIES WHEREIN METALLOPROTEINASES ARE INVOLVED - The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, pulmonary disease, and neoplastic pathologies. | 02-21-2013 |
20130072676 | USE OF POLYOLS TO OBTAIN STABLE POLYMORPHOUS FORMS OF RIFAXIMIN - Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. | 03-21-2013 |
20130183325 | MUCOADHESIVE XYLOGLUCAN-CONTAINING FORMULATIONS USEFUL IN MEDICAL DEVICES AND IN PHARMACEUTICAL FORMULATIONS - Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients. | 07-18-2013 |
20130281697 | POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 10-24-2013 |
20130287692 | RIFAMYCIN DERIVATIVES - Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: | 10-31-2013 |
20130289269 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention. | 10-31-2013 |
20140011828 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 01-09-2014 |
20140079783 | Pharmaceutical Compositions Comprising Rifaximin and Amino acids, Preparation Methods and Use Thereof - The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution. | 03-20-2014 |
20140112987 | GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 04-24-2014 |
20140186450 | GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 07-03-2014 |
20140235662 | RIFAXIMIN POWDER, PROCESS FOR PREPARING THE SAME AND CONTROLLED RELEASE COMPOSITIONS CONTAINING SAID RIFAXIMIN USEFUL FOR OBTAINING A LONG-LASTING EFFECT - The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient. | 08-21-2014 |
20140308350 | NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Described herein are methods and systems for treatment and/or prevention of conditions associated with NSAID administration and related compositions. | 10-16-2014 |
20140378495 | RIFAXIMIN DERIVATIVE AND USES THEREOF - 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided. | 12-25-2014 |
20150072002 | USE OF POLYOLS TO OBTAIN STABLE POLYMORPHOUS FORMS OF RIFAXMIN - Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described. | 03-12-2015 |
20150080421 | PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN, PROCESSES FOR THEIR OBTAINMENT AND METHOD OF TREATING INTESTINAL DISEASE - Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form β, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days. | 03-19-2015 |